• These were the worst-performing ASX 200 shares last week

    It was another quality week for the S&P/ASX 200 Index (ASX: XJO). Over the five days, the benchmark index climbed 115.9 points or 1.6% to end at a record high close of 7,295.4 points.

    Unfortunately, not all shares were able to follow the market’s lead. Here’s why these were the worst performing ASX 200 shares last week:

    Nuix Ltd (ASX: NXL)

    The Nuix share price was the worst performer on the ASX 200 last week with a disappointing 23.2% decline. The investigative analytics company’s shares were sold off again after it downgraded its guidance just over a month after issuing it. Nuix is now expecting pro forma revenue of $173 million to $182 million in FY 2021. This compares to its 21 April guidance of $180 million to $185 million. Management blamed this latest downgrade on the timing of closure of some upsell opportunities and new potential customers.

    Silver Lake Resources Limited (ASX: SLR)

    The Silver Lake share price was out of form and sank 12.6% last week. This appears to have been driven largely by weakness in the gold price. Silver Lake wasn’t the only gold miner that was under pressure. This led to the S&P/ASX All Ords Gold index losing 3.5% of its value over the five days.

    Mesoblast limited (ASX: MSB)

    The Mesoblast share price was a poor performer and dropped 8.9%. Investors were selling the allogeneic cellular medicines company’s shares following its third quarter update. During the quarter, the company reported a loss after tax of US$26.5 million. This brought its financial year to date loss to US$76.75 million. Fortunately, thanks to a US$110 million private placement in March, the company finished the period with a cash balance of US$158.3 million. Management believes this is sufficient to meet its short-term goals, commitments, and ongoing operations during the next twelve months.

    Appen Ltd (ASX: APX)

    The Appen share price was just a fraction behind with a decline of almost 8.9% over the five days. This was driven by weakness in the tech sector and news that the artificial intelligence data services company’s CEO, Mark Brayan, has sold 109,430 Appen shares. Mr Brayan received a total consideration of $1.43 million for the shares. Though, it is worth noting that the sale was made to satisfy tax obligations arising from the vesting of 173,153 performance rights.

    The post These were the worst-performing ASX 200 shares last week appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3g8rPU1

  • Got cash to invest? Here are 2 ASX shares that could be buys

    Some ASX shares could be really good ideas to look at right now.

    Share prices and profit outlooks are always changing, so different investments might seem like opportunities at different times.

    Sonic Healthcare Ltd (ASX: SHL)

    Sonic is one of the world’s largest healthcare businesses in the pathology space. It’s operating in a number of different countries including USA, Germany, Australia, the UK, Ireland, Switzerland, Belgium and New Zealand.

    It has grown a lot over the last two decades. But the last 15 months has seen revenue rise and profit explode.

    Sonic’s COVID-19 testing capability continues to play an important role in pandemic control. At the time of the FY21 half-year result, it had conducted more than 18 million COVID-19 PCR tests.

    The business has been able to utilise its existing infrastructure, laboratories and so on to provide the testing services.

    In the first half of FY21, revenue grew 33% to $4.4 billion, earnings before interest, tax, depreciation and amortisation (EBITDA) went up 89% to $1.3 billion and net profit after tax (NPAT) grew 166% to $678 million.

    Not only does Sonic think that COVID-19 testing is going to continue for the foreseeable future, there’s also the potential for growing demand for COVID-19 immunity testing.

    In terms of the outlook, Sonic said there are increasing acquisition, contract and joint venture growth opportunities. This growth potential could be supported by a “very strong” balance sheet.

    The ASX share has pointed out that its geographical diversification gives it more opportunities for expansion. Management said the underlying healthcare growth drivers are strong and unchanged.

    VanEck Vectors Video Gaming and eSports ETF (ASX: ESPO)

    This exchange-traded fund (ETF) is invested in some of the world’s leading companies involved in video game development, eSports, and related hardware and software globally.  

    Almost two thirds of the portfolio is invested in ‘entertainment’, like video game creators. But there are other sectors in the portfolio like semiconductors, semiconductor equipment, video game accessories and so on.

    There are 25 holdings in the portfolio, with businesses such as Nvidia, Tencent, Nintendo, Bandai Namco, Zynga, Activision Blizzard and Ubisoft in the mix.

    VanEck says e-sports reflects the convergence of entertainment, video gaming, sports and media businesses. With an active, engaged and relatively young demographic, the “stage is set for sustainable long-term growth”.

    eSports revenue has grown by an average of 28% per annum since 2015. It’s benefiting from game publisher fees, media rights, merchandise, ticket sales and advertising.

    The Asia Pacific region is estimated to have generated game revenue of US$78.4 billion in 2020, accounting for almost half of the global games market.

    VanEck says another reason to consider this investment is that it provides technology diversification away from the typical companies of Apple, Amazon, Facebook, Google and Microsoft.

    The post Got cash to invest? Here are 2 ASX shares that could be buys appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3ciJlUy

  • Do ASX share portfolios provide enough diversification?

    Ah, diversification… One of the most common terms you’re likely to hear in the finance world. Almost every financial advisor, commentator, and drover’s dog out there will tell you that having a diversified portfolio is a good thing. You know, don’t have all your eggs in one basket and all that.

    But you might hear of some investors constructing a ‘balanced’ portfolio, diversifying their S&P/ASX 200 Index (ASX: XJO) shares with other assets like fixed-interest government bonds, property, or even gold. You might have even come across the concept of the ’60/40 portfolio’ (60% shares, 40% bonds) that is popular over in the United States. So is this a ‘must-do’? Let’s check it out.

    Is balance always a good thing?

    Well, to understand why some investors advocate for a ‘balanced’ portfolio, you have to understand what the underlying goal is. For these investors, it’s balancing potential growth with volatility. Most of us don’t really like to see the values of our share portfolios bounce around every time there is market volatility. Most of us would prefer (even if it’s deep down) to see our portfolios rise in a perfectly linear way. But that’s not what the share market gives us, at least most of the time. Now some investors enjoy this volatility, and the opportunities to buy shares ‘on sale’ that it can bring. Others hate it, and may even panic when they see their shares drop in value.

    The latter investor is what a balanced portfolio is designed to cater for. The premise is simple – expose your wealth to long-term growth assets like shares, but balance the shares out with another asset class that provides lower returns, but increased stability.

    In this way, you are aiming for the best of both worlds – growth with less volatility.

    Diversification isn’t always free

    However, since there is no such thing as a free lunch, there is always a trade-off. You usually can’t expect a portfolio that invests in stabilising asset classes to perform as well as a portfolio that’s geared for maximum growth. It’s one, the other, or a middle road between the two.

    For some investors, this might be a sound idea. If you hate the idea of seeing your portfolio lose money, or experience mental distress during periods of severe market volatility, like a crash, then perhaps diversification into different asset classes may be a good idea. There are many ASX exchange-traded funds (ETFs) that can be used for this purpose. Some include the ETFS Physical Gold ETF (ASX: GOLD), or the Vanguard Australian Fixed Interest Index ETF (ASX: VAF). But if you’re an investor who wants to maximise returns, with little regard for volatility, then there might not be any reason to look to diversify. Shares, including ASX shares, are one of the (if not the) best-performing asset classes if you take a long time horizon. The ASX 200 has beaten the long term returns of government bonds and gold since Federation, and handily so.

    So like most things in life, there is no ‘right answer’ here when it comes to portfolio diversification. Only what’s best for you, your portfolio, your investing goals, and risk tolerance.

    The post Do ASX share portfolios provide enough diversification? appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3yYMnXL

  • 2 top ASX dividend shares rated as buys

    Are you looking for some dividend options for your portfolio in June? Then check out the two ASX shares listed below.

    Here’s why these ASX dividend shares have been tipped to as buys this month:

    Bapcor Ltd (ASX: BAP)

    The first ASX dividend share to look at is Bapcor. It is the Asia Pacific’s leading provider of vehicle parts, accessories, equipment, service and solutions. It is also the name behind a number of retail brands such as Autobarn, Burson Auto Parts and Midas.

    Bapcor has been performing very strongly in FY 2021 thanks to strong demand for used cars. This has resulted in elevated sales across its brands.

    Positively, the company looks well-placed to continue its growth in the future. This is thanks to its strong market position and its expansion plans. The latter is being driven both domestically and in the Asia market.

    According to a note out of Citi, its analysts are expecting Bapcor to grow its fully franked dividend to 19 cents per share in FY 2021 and then 22 cents per share in FY 2022. Based on the current Bapcor share price of $8.17, this will mean yields of 2.3% and 2.5%, respectively.

    Citi has a buy rating and $9.50 price target on the company’s shares.

    Scentre Group (ASX: SCG)

    Times may have been hard for this shopping centre-focused property company, but the worst could now be over.

    That’s the view of analysts at Goldman Sachs. Late last month the broker reiterated its buy rating and $3.60 price target on the company’s shares.

    Goldman notes that Australian inflation expectations are currently at their highest level since 2015. This is a big positive for Scentre, with the broker’s analysis suggesting that Scentre is far more positively leveraged to inflation than any other Australian real estate investment trusts under its coverage.

    Goldman is forecasting a 14 cents per share dividend in FY 2021. Based on the latest Scentre share price of $2.80, this equates to a 5.2% yield.

    The post 2 top ASX dividend shares rated as buys appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3xbUlLt

  • When the music stops… the investment bankers stop getting paid!

    You’ve heard the one about The Beatles’ album which, when played backwards, says ‘Paul is dead’, right?

    It was a fun conspiracy theory (though it was a simpler time — imagine what they’d find on it these days with 5G chips in every COVID vaccination!).

    It was, of course, untrue.

    I haven’t had my COVID vaccine yet (they’re booked out!), but I expect my phone signal to improve when I do.

    (I can’t decide whether to make sure you know I’m kidding, or just watch the emails roll in from those who think I’m serious. Somehow, I don’t think I’m going to stop them, either way, but for the record, I’ll be getting the jab as soon as I can. And no, it’s not some Bill Gates New World Order plot.)

    Now, where was I?

    That’s right — songs being played backwards.

    There’s something of an ASX analogy — it’s not a conspiracy, but it’s equally silly — which plays out, in one form or another, almost continuously.

    It’s the forwards-backwards dance of acquisition-and-spinoff, merger-and-demerger.

    The latest, of course, is Westpac’s reported consideration of parting ways with its New Zealand operations.

    That news comes on the heels of Treasury Wine Estates (I own shares) considering spinning off the Penfolds brand.

    And Crown, back in the day, trying to list its property assets in a separate entity.

    Woolies is about to spin off Endeavour Drinks.

    It’s kind of a trend.

    But it’s not a one-way story.

    Google (I own shares) once-upon-a-time bought YouTube.

    IOOF has acquired MLC.

    Ramsay Health is buying UK hospitals.

    Carsales bought 49% of a US classifieds mob.

    And there’s Tabcorp, which is either being taken over, selling assets, or spinning them off. It kinda depends what day it is!

    Then there’s the merry-go-round:

    It wasn’t that long ago that Treasury itself was merged into Carlton & United Breweries. Then spun out.

    Or that long ago that our banks bought into NZ, and strapped on wealth management arms (now also all-but gone).

    Woolies bought — and then sold — EziBuy, the online catalogue retailer.

    BHP has had as chequered a career as anyone on that front, too.

    You’d almost be forgiven — and forgive me, as I drop into an almost-conspiratorial whisper — for thinking that the common thread here is ‘activity’, maybe even encouraged by investment banks and brokers who (I know, I’m surprised too), stand to make a cut of the transaction.

    Surely not.

    Right?

    Well, I’ll let you make your own decision on that one.

    What I will say is that CEOs and company boards, like the rest of us, find it bloody hard to resist the temptation to just leave things alone.

    They feel compelled to tinker, driven by the idea that they might be able to ‘create value’ through the ‘synergies’ of a merger, or the ‘increased focus’ of a divestiture.

    That both can’t be simultaneously true seems to elude them, or perhaps they just think they’re the exception to the rule.

    After all, CEOs don’t get the big chair by lacking confidence…

    And the blame doesn’t lie just with CEOs, either.

    We investors are happy to accept — or sometimes even encourage — the sort of thinking that gives us what I’ve decided to call ‘piano accordion capitalism’(™).

    In. Out. In. Out. In. Out.

    When we bid up a company’s share price after they announce a merger, we’re implicitly approving the decision.

    When one company becomes two — and the market capitalisation of the two businesses is higher than when they were a single company — we’re justifying the decision.

    Why wouldn’t a CEO do those things, when they’re given share price ‘applause’ as a result?

    We’re also very fickle, though — if things don’t work out, we’re only too happy to knife the incumbent and blame him for our problems.

    It’s good to be the king.

    So which is it?

    Should we be cheering on mergers?

    Or pushing for divestments?

    Or should we be wary of acquisitions and preferring our companies to keep their businesses intact?

    Alas, dear reader, there is no easy answer.

    There are plenty of cases that support the ‘don’t just sit there, do something’ approach, and plenty of cases that make you wish the top brass had just played golf that day, instead.

    Which is, in its way, the point.

    If something is a crapshoot, doesn’t it stand to reason that, for all of the costs, hassle, disruption and uncertainty, the better course of action is just to leave well enough alone?

    It’s a pipedream, of course.

    CEOs spend their lives with investment bankers and short-term investors in their ears; exhorting them, in Warren Buffett’s baseball metaphor, to ‘swing, ya bum’!

    And so, the decision falls to us, as investors.

    If we can’t control the CEOs and boards, we can at least control our own emotions and decisions.

    And we can remember that the motivation of those who would make these things happen is almost always short-term in nature. So, the bottom line is, unfortunately, that we should be sceptical.

    As a Treasury shareholder, I hope the company resists the urge to demerge its crown jewel, even if, in the short term, the combined price jumps a little.

    If I was a bank shareholder, I’d want Westpac to keep its NZ operations — and I’m on record as saying I think the banks will rue spinning off their wealth management businesses. After all, long term mortgage debt can only rise as fast as wages (plus or minus any change in interest rates), while wealth management has a long term, compounding, tailwind!

    Again, though, some spin offs will be good for shareholders. And some acquisitions will truly create long term value.

    So there’s no easy answer other than, as Buffett’s right hand man Charlie Munger would suggest, to keep an eye on the incentives at play — and to keep a slightly sceptical countenance.

    (Alternatively, if you want to buy all of the parts of my car for more than the market is offering for the whole thing, give me a call. I’m sure we can come to an arrangement!)

    Fool on!

    The post When the music stops… the investment bankers stop getting paid! appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3w5SMhC

  • 3 reasons why the VanEck Vectors Morningstar Wide Moat ETF (ASX:MOAT) could be a quality investment

    The VanEck Vectors Morningstar Wide Moat ETF (ASX: MOAT) could be a really interesting exchange-traded fund (ETF) investment to think about.

    There are a number of different reasons why this ETF could offer some good characteristics to investors.

    Here are three reasons to consider it:

    Quality

    Morningstar analysts are the people responsible for deciding which businesses make it into the portfolio, hence why it’s part of the ETF’s name. Only businesses with a strong economic moat can make it into the portfolio.

    Morningstar analysts assign an economic moat rating to each of the approximately 1,500 companies under its coverage.

    An economic moat is a sustainable competitive advantage that allows a company to generate positive economic profits for owners over an extended period.

    For a company to be assessed to have a wide economic moat, excess normalised returns must, with near certainty, be positive 10 years from now. In addition, excess normalised returns must, more likely than not, be positive 20 years from now.

    The duration of forecast profit is far more important for Morningstar than the absolute magnitude.

    Diversification

    Whilst all of the businesses in this portfolio are listed in the US, they offer satisfactory levels of diversification.

    It has a high allocation to growing sectors and a small weighting to slow-growth industries. At the end of April 2021, the weightings were: healthcare (20.4%), information technology (17%), industrials (15.2%), financials (12.9%), consumer staples (11%), communication services (7.2%), consumer discretionary (6.2%), materials (5%), energy (2.7%) and utilities (2.4%).

    VanEck Vectors Morningstar Wide Moat ETF doesn’t own hundreds of shares, but it has around 50 positions. This may provide a satisfactory level of diversification.

    There isn’t a lot of position concentration. The largest position in the portfolio is a 3.2% allocation to Wells Fargo. Other positions in the top 10 include: Cheniere Energy, Alphabet, Northrop Grumman, Philip Morris, Raytheon Technologies, General Dynamics, Berkshire Hathaway, Blackbaud and Altria.

    Other positions further down the portfolio include Yum! Brands, Constellation brands, Lockheed Martin, Boeing, Kellogg, Pfizer, Intel, Amazon and Salesforce.com.

    Outperformance in net return terms

    Past performance is not an indicator of future returns, however the historical net returns of VanEck Vectors Morningstar Wide Moat ETF have been better than the S&P 500 over the shorter-term and the longer-term.

    Over the six months to 30 April 2021, the ETF’s total return was 25% compared to the S&P 500’s return of 16.9%. Over the last five years the ETF has delivered an average return per annum of 18.6%, compared to the S&P 500’s average return per annum of 16.5%.

    The post 3 reasons why the VanEck Vectors Morningstar Wide Moat ETF (ASX:MOAT) could be a quality investment appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/2RqLQgc

  • DGL Group (ASX:DGL) share price falls despite positive announcement

    The DGL Group Ltd (ASX: DGL) share price headed south today despite the company announcing its growth initiatives are underway.

    At the end of market trade, the chemical company’s shares were swapping hands for $1.26, down 2.69%.

    What did DGL announce?

    DGL couldn’t catch a break today, with investors offloading the company’s shares despite its positive release.

    According to the statement, the DGL board has approved plans to develop its new chemicals storage warehouse.

    DGL will seek to expand commercial operations at its existing Mount Wellington warehousing and distribution facility in Auckland, New Zealand. The cost to develop the warehouse is expected to be around NZ$4.5 million (A$4.2 million).

    Construction works have been awarded to Robert Cunningham Construction, which has more than 25 years’ experience in the industry. Furthermore, the project will be managed by New Zealand’s leading independent project management company, MPM Projects.

    Construction of the warehouse will begin in July, with completion scheduled for the end of the year.

    Management commentary

    DGL founder and CEO Simon Henry said of the expansion plans:

    Mount Wellington is a large, sought-after and key distribution hub for the Auckland metro region. The new state-of-the-art facility will provide increased storage for current clients and enable new clients to gain access to the precinct. We expect the warehouse to be fully occupied soon after opening.

    The new warehouse is the first of a number of site expansions planned across the Trans-Tasman in the next 12 months, to ensure that we are able to provide the capacity the industry requires and to further cement our position as the leading service provider to the chemical industry in Australia and New Zealand.

    More on the warehouse

    DGL acquired the 1.8-hectare site in 2012, and the company has spent 9 years bringing its specialised chemical storage facility online.

    The Mount Wellington site is currently licenced to store up to 6,000 tonnes of chemicals. The new warehouse will provide the company with an additional 2,000 tonnes of capacity. It will take DGL’s total capacity to 128,000 tonnes across all its facilities from Perth, Western Australia to Christchurch.

    DGL share price snapshot

    Operating across Australia, New Zealand and internationally, DGL offers chemical formulation and manufacturing services, warehousing and distribution, waste management, and environmental solutions.

    Since listing on the ASX early last week at a price of $1.00 per share, the DGL share price has gained 26%. Based on the current share price, the company has a market capitalisation of roughly $325 million.

    The post DGL Group (ASX:DGL) share price falls despite positive announcement appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3uWp5i0

  • Why the Antisense (ASX:ANP) share price rocketed 16% today

    The Antisense Therapeutics Limited (ASX: ANP) share price soared today without any news out of the company. It seems the market may have been a bit slow on the uptake and was responding to news released by the junior healthcare company earlier in the week. On Tuesday, Antisense released an announcement regarding a muscular dystrophy study.

    The company provided an update on its meeting with the United States Food and Drug Administration (FDA) in relation to the inhibitor ATL1102. At close of trading today, the biotechnology company’s shares were up 15.79% to 22 cents. This followed gains on Thursday’s session as well.

    What’s drove the Antisense share price higher?

    The rise in Antisense shares followed the release earlier this week of the FDA’s official minutes on the company’s Type C guidance meeting.

    According to the statement, the FDA has given the nod for Antisense to explore higher dosage limits of ATL1102 in future studies. This follows the recent data findings of Antisense’s Phase II open-label study in Melbourne. A total of 9 Duchenne muscular dystrophy (DMD) patients received 25 milligrams of ATL1102 per week for 24 weeks.

    Furthermore, Antisense said the FDA has accepted the company’s proposed design of its Phase IIb/III study. The clinical trial will run for 52 weeks during which time participants will be assessed for muscle strength. The FDA also suggested Antisense submits a study protocol, outlining primary and secondary endpoints.

    A 9-month monkey toxicology study will also be conducted into the effects of ATL1102. However, the FDA said once the animal study is at the report-writing stage, the Phase IIb/III human trial can begin.

    Antisense is now consulting with US-based regulatory advisors regarding the next steps towards starting the Phase IIb/III human trial. In addition, the company is evaluating the cost and feasibility of the 9-month monkey study.

    About Antisense and ATL1102

    Founded in 2000, Antisense is focused on developing and commercialising antisense pharmaceuticals for patients suffering from rare diseases. Antisense is the non-coding DNA strand of a gene.

    The company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for DMD patients. Recently Antisense reported promising Phase II trial results, indicating a significantly reduced number of brain lesions in patients with relapsing-remitting multiple sclerosis.

    DMD is a severe type of muscular dystrophy that primarily affects boys. According to Antisense, it occurs as a result of mutations in the dystrophin gene which cause a substantial reduction in, or absence of, the dystrophin protein.

    Ongoing deterioration in muscle strength affects lower limbs, leading to impaired mobility, and can also affect upper limbs, leading to further loss of function and self-care ability.

    Over the past 12 months, the Antisense share price has jumped by almost 230%. Antisense shares are also up by around 70% year to date.

    The post Why the Antisense (ASX:ANP) share price rocketed 16% today appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3ifOO20

  • 3 highly rated ASX growth shares analysts love

    There are a lot of growth shares for investors to choose from on the Australian share market.

    To narrow things down, I have picked out three ASX growth shares that are highly rated. Here’s what you need to know about them:

    ELMO Software Ltd (ASX: ELO)

    ELMO is a HR and payroll platform provider. It has been growing at an impressive rate over the last few years thanks to solid demand for its offering in the ANZ and UK markets and acquisitions. Positively, the company looks well-placed to continue this positive form thanks to the shift to the cloud, its significant addressable market, and cross- and up-selling opportunities.

    One broker that is particularly positive on ELMO is Shaw & Partners. It currently has a buy rating and and $9.00 price target.

    IDP Education Ltd (ASX: IEL)

    IDP Education is a provider of international student placement services and English language testing services. As you might expect, it was hit hard by the pandemic. However, thanks to its software business and strong balance sheet, the company has been tipped to win market share and resume its rapid growth once the crisis passes.

    Morgan Stanley is positive on the company’s post-pandemic prospects. As a result, it recently retained its overweight rating and $30.00 price target on the IDP Education’s shares.

    ResMed Inc. (ASX: RMD)

    Another growth share to look at is ResMed. It is a medical device company with a focus on the sleep treatment market. Thanks to its industry-leading products, wide distribution, and successful acquisitions, ResMed has been growing at a very strong rate over the last few years. Pleasingly, thanks to its significant market opportunity and the growing prevalence of sleep disorders, it has been tipped to continue doing so for the foreseeable future.

    Credit Suisse is a fan of the company and believes upcoming launch of its new CPAP device, AirSense 11, will be a key driver of growth. The broker has an outperform rating and $29.00 price target on its shares.

    The post 3 highly rated ASX growth shares analysts love appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3g8LvHd

  • These 3 shares were the biggest gainers of the ASX 200 this week

    It’s been a good week for the S&P/ASX 200 Index (ASX: XJO), which has gained 1.68% since last Friday’s close. Though, these 3 shares have blown the ASX 200’s gains out of the water.

    Let’s take a look at this week’s best performing shares of the index.

    This week’s top performers

    Origin Energy Ltd (ASX: ORG) – up 15.7%

    Origin shares enjoyed a stellar week on the ASX despite there being no news out of the company.

    But, as Motley Fool reported yesterday, the ASX 200 energy producer’s share price has been boosted by surging commodity prices, which underpinned solid gross domestic product (GDP) growth.

    By the end of the week, the Origin Energy share price was trading at $4.72.

    Worley Ltd (ASX: WOR) – up 15.6%

    Since last Friday’s close, the Worley share price has gained an impressive 15.6% as a result of multiple announcements.

    On Tuesday, the ASX 200 engineering company announced 2 contract wins – one with Celanese and another with Shell.

    Worley’s contract with Celanese will see it conducting the engineering, procurement and construction of Celanese’s new acetic acid unit in Texas, United States.

    Its contract for Shell will involve building a green hydrogen hub in the Netherlands.

    Despite the good news, the Worley share price dropped during Tuesday’s trade – closing 0.5% lower than its previous session.

    Luckily for shareholders, however, on Wednesday Worley released its investor day presentation. The presentation indicated that the company is set to deliver improved performance for the second half of the 2021 financial year.

    Finally, Worley received multiple positive broker notes on Thursday as a result of its investor day presentation.

    At Friday’s close, Worley shares were fetching $12.25 apiece.

    Inghams Group Ltd (ASX: ING) – up 12.2%

    This week, the Inghams share price seems to have been still basking in the glory of the company’s 2021 financial year earnings and guidance update, released last Friday.

    The guidance seemed to exceed the market’s expectations, since the company’s shares gained 10% that day.

    Then, on Monday, a note out of Goldman Sachs sent the poultry producer’s share price soaring once more when analysts retained their buy rating and lifted their price target on the Inghams share price to $4.50.

    On Wednesday, Credit Suisse followed Goldman Sachs’ example. Credit Suisse retained its outperform rating on Inghams shares and lifted its price target to $4.10

    Currently, one share in Inghams will set an investor back $3.83.

    The post These 3 shares were the biggest gainers of the ASX 200 this week appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3uKnpYE